Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Interest Expenses (2020 - 2025)

Historic Interest Expenses for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to $13000.0.

  • Barinthus Biotherapeutics' Interest Expenses fell 2352.94% to $13000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $50000.0, marking a year-over-year increase of 416.67%. This contributed to the annual value of $53000.0 for FY2024, which is 8928.57% up from last year.
  • Barinthus Biotherapeutics' Interest Expenses amounted to $13000.0 in Q3 2025, which was down 2352.94% from $12000.0 recorded in Q2 2025.
  • In the past 5 years, Barinthus Biotherapeutics' Interest Expenses registered a high of $2.6 million during Q1 2021, and its lowest value of $7000.0 during Q3 2023.
  • For the 5-year period, Barinthus Biotherapeutics' Interest Expenses averaged around $220076.9, with its median value being $13000.0 (2025).
  • As far as peak fluctuations go, Barinthus Biotherapeutics' Interest Expenses plummeted by 9931.58% in 2021, and later surged by 14285.71% in 2024.
  • Over the past 5 years, Barinthus Biotherapeutics' Interest Expenses (Quarter) stood at $18000.0 in 2021, then soared by 311.11% to $74000.0 in 2022, then crashed by 90.54% to $7000.0 in 2023, then skyrocketed by 71.43% to $12000.0 in 2024, then increased by 8.33% to $13000.0 in 2025.
  • Its Interest Expenses stands at $13000.0 for Q3 2025, versus $12000.0 for Q2 2025 and $13000.0 for Q1 2025.